Introducing the Safety & Efficacy of CONV01-Alpha for the Treatment of Men with Advanced Prostate Cancer
- Delivering a potent alpha-emitting payload directly to PSMA-expressing mCRPC cells via an antibody platform, improving tumor specificity while minimizing exposure to healthy tissues
- Avoiding key limitations of small-molecule alpha radiotherapies, including rapid renal clearance and non-specific uptake, through controlled antibody-based biodistribution
- Enabling a differentiated safety–efficacy balance in advanced prostate cancer by combining high-energy alpha radiation with precise PSMA targeting